C. H.Chen |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=1.414 ------>paper_class3=2 ------>paper_class2=1 ------>vol=26 ------>confirm_bywho=None ------>insert_bywho=enochlai49 ------>Jurnal_Rank=81.8 ------>authors4_c= ------>comm_author= ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=3716 ------>medlineContent= ------>unit=000 ------>insert_date=20090311 ------>iam=7 ------>update_date=None ------>author=??? ------>change_event=1 ------>ISSN= ------>authors_c= ------>score=500 ------>journal_name=Anticancer research ------>paper_name=Post-operative concurrent chemoradiation therapy using oral Uracil-tegafur versus weekly intravenous Fluorouracil for locally advanced rectal cancer ------>confirm_date=None ------>tch_id=083041 ------>pmid=17094389 ------>page1=3709 ------>fullAbstract=BACKGROUND: This prospective, nonrandomized study was conducted to compare the efficacy and toxicity of post-operative concurrent chemoradiation therapy (CCRT) using daily oral uracil-tegafur plus leucovorin (UFUR/LV) vs. weekly intravenous fluorouracil plus leucovorin (5-FU/LV) in patients with locally advanced rectal cancer. MATERIALS AND METHODS: From November 1996 through December 2004, 30 patients with stage II or III rectal cancer were enrolled. Either 5-FU (400 to 450 mg/m2) plus LV (80 to 100 mg/m2) weekly or oral UFUR (250 to 300 mg/m2/d) plus oral LV (30 to 45 mg/m2/d) were given during radiotherapy. Radiation (50.4 to 60.4 Gy) was delivered to the tumor bed in 28-33 fractions. RESULTS: The mean survival, 2-year overall survival and disease-free survival were 36 months vs. 30 months, 68% vs. 66% and 55% vs. 50%, (p > 0.05), in the UFUR/LV and 5-FU/LV groups, respectively. There were no treatment-related deaths or grade 4 toxicity in either group. Grade 3 dermatitis, gastrointestinal and hematologic toxicity were noted in the 5-FU/LV group. CONCLUSION: Because of a similar survival rate and lower toxicity, oral UFUR/LV is suggested as an alternative regimen to intravenous 5-FU/LV in post-operative CCRT of locally advanced rectal cancer. ------>tmu_sno=None ------>sno=21312 ------>authors2=Y. J.Chen ------>authors3=K. H.Chang ------>authors4=H. H.Hsu ------>authors5=C. K.Liu ------>authors6=S. K.Hung, H. W.Chen, Y.L.LAi, T. C.Hsu ------>authors6_c= ------>authors=C. H.Chen ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Post-operative concurrent chemoradiation therapy using oral uracil-tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no= ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2006 ------>submit_flag=None ------>publish_month=1 |